These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21109688)

  • 1. Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.
    van Loenen MM; de Boer R; Hagedoorn RS; van Egmond EH; Falkenburg JH; Heemskerk MH
    Haematologica; 2011 Mar; 96(3):477-81. PubMed ID: 21109688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.
    Heemskerk MH; Hoogeboom M; de Paus RA; Kester MG; van der Hoorn MA; Goulmy E; Willemze R; Falkenburg JH
    Blood; 2003 Nov; 102(10):3530-40. PubMed ID: 12869497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.
    Griffioen M; van Egmond HM; Barnby-Porritt H; van der Hoorn MA; Hagedoorn RS; Kester MG; Schwabe N; Willemze R; Falkenburg JH; Heemskerk MH
    Haematologica; 2008 Oct; 93(10):1535-43. PubMed ID: 18768532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modification of Cytotoxic Lymphocytes with T Cell Receptor Specific for Minor Histocompatibility Antigen ACC-1Y].
    Pilunov AM; Kuchmiy AA; Sheetikov SA; Filkin SY; Romaniuk DS; Rosov FN; Efimov GA
    Mol Biol (Mosk); 2019; 53(3):456-466. PubMed ID: 31184611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
    Biernacki MA; Brault M; Bleakley M
    Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer.
    Mommaas B; van Halteren AG; Pool J; van der Veken L; Wieles B; Heemskerk MH; Goulmy E
    Haematologica; 2005 Oct; 90(10):1415-21. PubMed ID: 16219579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.
    van Loenen MM; Hagedoorn RS; de Boer R; van Egmond EH; Falkenburg JH; Heemskerk MH
    J Immunother; 2011 Mar; 34(2):165-74. PubMed ID: 21304404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
    van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
    Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
    Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
    Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adoptive immunotherapy using gene-modified T cells to express target-specific receptors against hematological malignancy].
    Fujiwara H
    Rinsho Ketsueki; 2014 Oct; 55(10):2162-74. PubMed ID: 25297783
    [No Abstract]   [Full Text] [Related]  

  • 12. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.
    Heemskerk MH; Hoogeboom M; Hagedoorn R; Kester MG; Willemze R; Falkenburg JH
    J Exp Med; 2004 Apr; 199(7):885-94. PubMed ID: 15051765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function.
    Thomas S; Mohammed F; Reijmers RM; Woolston A; Stauss T; Kennedy A; Stirling D; Holler A; Green L; Jones D; Matthews KK; Price DA; Chain BM; Heemskerk MHM; Morris EC; Willcox BE; Stauss HJ
    Nat Commun; 2019 Oct; 10(1):4451. PubMed ID: 31575864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
    van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
    Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells.
    van Loenen MM; Hagedoorn RS; Kester MG; Hoogeboom M; Willemze R; Falkenburg JH; Heemskerk MH
    Cancer Res; 2009 Mar; 69(5):2034-41. PubMed ID: 19223543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.
    Heemskerk MH; Hagedoorn RS; van der Hoorn MA; van der Veken LT; Hoogeboom M; Kester MG; Willemze R; Falkenburg JH
    Blood; 2007 Jan; 109(1):235-43. PubMed ID: 16968899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells.
    Sommermeyer D; Uckert W
    J Immunol; 2010 Jun; 184(11):6223-31. PubMed ID: 20483785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell receptor gene-modified cells: past promises, present methodologies and future challenges.
    Tendeiro Rego R; Morris EC; Lowdell MW
    Cytotherapy; 2019 Mar; 21(3):341-357. PubMed ID: 30655164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.